InvestSMART

Archer Materials Limited (ASX:AXE)

ALERT: Price-sensitive ASX Announcement for AXE
Current share price for AXE : $0.160 -0.065 (-28.89%)+
Announcement
Release
13 Aug 2026 9:27AM
Price at Release
$0.225
Full Release
download
Summary
Archer Materials Limited conducted an early-stage study involving 20 donors to advance its potassium biosensor technology, focusing on optimizing blood collection methods to reduce haemolysis, which can affect potassium measurements. The study identified promising capillary blood collection techniques with haemolysis levels comparable to traditional venous methods. These findings are crucial for the engineering of Archer's beta prototype and will guide future pilot studies and regulatory engagements, including a Pre-Submission to the FDA. The research marks a significant step in integrating biosensor components into a complete system, addressing challenges in measuring and managing haemolysis, which is vital for accurate blood potassium testing.
Key Points
  • Archer Materials completed an early-stage blood collection study with 20 donors for potassium biosensor development.
  • Capillary blood collection approaches were evaluated, identifying methods with low haemolysis comparable to conventional venous collection.
  • The study supports engineering the beta prototype and optimizing blood sample collection and processing workflows.
  • Results will inform future pilot and pivotal study designs and contribute to regulatory engagement, including an FDA Pre-Submission.
  • The study helps transition from individual biosensor components to an integrated system for future clinical evaluation.
  • Haemolysis measurement is critical as it affects blood potassium testing by potentially releasing additional potassium into samples.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.